Cumberland Pharmaceuticals Inc. — FY2023 Form 10-K Summary
Business context and reporting period
Cumberland is a specialty pharmaceutical company focused on acquiring, developing and commercializing branded prescription products in hospital acute care, gastroenterology and oncology. The filing covers the fiscal year ended December 31, 2023; fourth-quarter 2023 results are included in the annual filing. The company marketed seven FDA-approved products and advanced Phase II programs for ifetroban in systemic sclerosis, Duchenne muscular dystrophy cardiomyopathy and idiopathic pulmonary fibrosis.
Financial performance and key metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net revenues | $39.6 million | $42.0 million | Down $2.5 million, or 5.9% |
| Gross profit | $33.5 million | $32.9 million | Up $0.6 million |
| Gross margin | 84.7% | 78.3% | Improved |
| Operating loss | $(9.6) million | $(5.7) million | Worsened by $3.8 million |
| Operating margin | (24.2%) | (13.6%) | Worsened |
| Net loss attributable to common shareholders | $(6.3) million | $(5.6) million | Worsened by $0.7 million |
| Loss per share | $(0.44) | $(0.38) | Worsened |
| Operating cash flow | $6.1 million | $8.5 million | Down $2.4 million |
Gross profit and gross margin benefited from lower product costs and fewer inventory write-downs. However, the company remained loss-making because of selling and marketing costs, research and development, general and administrative expenses, and higher amortization and impairment charges. The $8.1 million amortization and impairment expense included a $3.3 million non-cash write-down of Omeclamox-Pak intangible assets.
| 2023 product revenue | Revenue | Change versus 2022 |
|---|---|---|
| Kristalose | $16.0 million | Up 5.1% |
| Vibativ | $8.8 million | Up 17.7% |
| Sancuso | $8.1 million | Down $5.1 million |
| Caldolor | $4.3 million | Down $0.5 million |
| Acetadote | $0.5 million | Broadly stable |
| Vaprisol | $0.2 million | Prior-year amount included negative revenue adjustments; no commercial inventory was available in 2023 |
| Omeclamox-Pak | $0.02 million | Effectively unavailable due to packaging disruption |
Other revenue was $2.0 million, including approximately $1.0 million related to a Vibativ litigation settlement, approximately $2.8 million of FDA fee refunds, approximately $0.5 million of manufacturing-dispute settlement income and approximately $0.3 million of insurance proceeds. These items are unusual and not necessarily indicative of recurring operating performance.
Liquidity, debt and balance sheet
- Cash and cash equivalents were $18.3 million at December 31, 2023, compared with $19.8 million at year-end 2022.
- Working capital was $7.7 million versus $17.3 million in the prior year; the current ratio declined to 1.3 from 1.6.
- The company generated $6.1 million of operating cash flow, used $0.1 million in investing activities and used $7.4 million in financing activities.
- Debt outstanding under the revolving credit facility was $12.8 million, down from $16.2 million. The facility permits initial borrowings of up to $20 million and potential expansion to $25 million, matures October 1, 2026, and bears interest at Term SOFR plus 2.75%; the reported rate was 8.125% at year-end.
- Revolving credit availability was $7.2 million at year-end. The company stated that it was in compliance with its funded-debt-ratio covenant.
- Contractual obligations totaled approximately $31.1 million, including debt, estimated interest, contingent consideration and operating leases.
- The company repurchased 402,143 shares for approximately $0.7 million during 2023, leaving approximately $3.0 million available under the repurchase authorization.
Material changes versus the prior comparable period
- Revenue declined primarily because of lower Sancuso revenue, reflecting significant product returns and higher commercial rebates, and lower Caldolor revenue attributable to international shipment timing.
- Kristalose and Vibativ grew, with Vibativ benefiting substantially from fewer product returns.
- Selling and marketing expense increased $1.8 million to $18.5 million, mainly due to Sancuso royalties, promotional spending and expansion of the oncology sales division.
- Research and development expense declined $0.9 million to $5.8 million, primarily due to lower FDA fees. The company received approximately $2.8 million in FDA fee refunds during 2023.
- Amortization and impairment increased $3.0 million, primarily due to the Omeclamox-Pak write-down.
- Sancuso transition activities were completed, including transfer of the NDA and manufacturing to a new facility. Cumberland expected to begin shipping Cumberland-packaged product in 2024.
- The company discontinued RediTrex sales in 2023 after transferring U.S. responsibility back to Nordic Pharma and expects royalties on future Nordic sales through April 2035.
Guidance, outlook, risks and unusual items
The filing does not provide formal quantitative revenue or earnings guidance. Management expects internally generated cash flow, existing working capital and the revolving credit facility to fund operations, business development and capital expenditures for the foreseeable future, but also discloses risks that could require additional financing or operating reductions.
- Caldolor may qualify for separate Medicare reimbursement under the NOPAIN Act beginning in 2025; the company was awaiting CMS decisions regarding eligibility and reimbursement levels.
- Vaprisol remained commercially unavailable, while an interim compounded supply was introduced late in 2023 and was expected to begin selling in early 2024. Branded manufacturing approval depends on resolving FDA-related issues at the new facility.
- Omeclamox-Pak remained unavailable because of packaging difficulties; the company was seeking alternative packaging arrangements.
- Ifetroban development remained at the Phase II stage and depended on clinical results, enrollment, regulatory approval and eventual commercial acceptance.
- The business relies heavily on third-party manufacturers, distributors and suppliers. Manufacturing disruptions, FDA inspections, product shortages or quality issues could reduce revenue and impair intangible assets.
- Three wholesale customers each represented at least 10% of 2023 revenue and together represented 79%, creating significant customer concentration.
- Major risks include generic competition, patent challenges, reimbursement pressure, product liability, regulatory compliance, cybersecurity incidents, variable-rate debt, foreign-market execution and the need to retain key personnel.
- Management assessed internal control over financial reporting as effective. The independent auditor issued an unqualified opinion on the financial statements but was not engaged to opine on internal control effectiveness.
Most important facts for investors to verify
- Whether Sancuso revenue and margins recover after the 2023 product returns, rebate adjustments and manufacturing transition.
- Timing and regulatory status of Vaprisol commercial supply and the impact of any resumed sales.
- Whether Omeclamox-Pak can return to the market and whether additional intangible-asset impairment charges are required.
- Progress, enrollment, safety results and funding requirements for the three Phase II ifetroban programs.
- Actual availability and utilization of the revolving credit facility, interest-rate exposure and compliance with its financial covenant.
- Cash conversion, working-capital trends and the sustainability of positive operating cash flow despite recurring net losses.
- Customer concentration, product-return and rebate estimates, including the $7.6 million year-end sales-related accrual.
- Potential revenue impact from generic competition and expiration or enforcement of key product patents, including Acetadote and Sancuso.
- Whether the reported FDA fee refunds, litigation settlement proceeds and insurance income should be excluded when assessing recurring earnings.